Which has preferable valuation & earnings, NVCT or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A

Is NVCT or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -38.92% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% Corvus Pharmaceuticals N/A -38.92% -35.75%

Which has preferable earnings and valuation, CGEM or NVCT?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is CGEM or NVCT more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Nuvectis Pharma N/A -161.00% -98.88%

Which has better valuation and earnings, IVA or NVCT?

Nuvectis Pharma has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 154.86 -$400.67M N/A N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is IVA or NVCT more profitable?

Inventiva's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Nuvectis Pharma N/A -161.00% -98.88%

Nuvectis Pharma (NVCT) Competitors

$10.31 +0.51 (+5.20%)

Closing price 04:00 PM Eastern

Extended Trading

$9.67 -0.64 (-6.19%)

As of 07:56 PM Eastern

Compare

NVCT vs. COLL, CRVS, CGEM, IVA, and ALVO

Should you buy Nuvectis Pharma stock or one of its competitors? MarketBeat compares Nuvectis Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvectis Pharma include Collegium Pharmaceutical (COLL), Corvus Pharmaceuticals (CRVS), Cullinan Therapeutics (CGEM), Inventiva (IVA), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

How does Nuvectis Pharma compare to Collegium Pharmaceutical?

Nuvectis Pharma (NASDAQ:NVCT) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Collegium Pharmaceutical has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.06

In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.93 beat Collegium Pharmaceutical's score of 0.47 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvectis Pharma	Positive
Collegium Pharmaceutical	Neutral

Nuvectis Pharma has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Nuvectis Pharma's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

96.8% of Nuvectis Pharma shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nuvectis Pharma presently has a consensus price target of $10.00, suggesting a potential downside of 3.01%. Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 65.23%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Collegium Pharmaceutical beats Nuvectis Pharma on 12 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Corvus Pharmaceuticals?

Nuvectis Pharma (NASDAQ:NVCT) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Nuvectis Pharma has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.93 beat Corvus Pharmaceuticals' score of 0.38 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvectis Pharma	Positive
Corvus Pharmaceuticals	Neutral

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Corvus Pharmaceuticals' return on equity of -38.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Nuvectis Pharma currently has a consensus price target of $10.00, suggesting a potential downside of 3.01%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 198.69%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Corvus Pharmaceuticals beats Nuvectis Pharma on 9 of the 13 factors compared between the two stocks.

How does Nuvectis Pharma compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Nuvectis Pharma. MarketBeat recorded 9 mentions for Cullinan Therapeutics and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.37 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Nuvectis Pharma	Positive

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cullinan Therapeutics' return on equity of -51.45% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Cullinan Therapeutics currently has a consensus target price of $30.75, suggesting a potential upside of 155.19%. Nuvectis Pharma has a consensus target price of $10.00, suggesting a potential downside of 3.01%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cullinan Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cullinan Therapeutics beats Nuvectis Pharma on 8 of the 13 factors compared between the two stocks.

How does Nuvectis Pharma compare to Inventiva?

Inventiva (NASDAQ:IVA) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Inventiva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Nuvectis Pharma has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	154.86	-$400.67M	N/A	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Inventiva's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Nuvectis Pharma	N/A	-161.00%	-98.88%

In the previous week, Inventiva had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 4 mentions for Inventiva and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.93 beat Inventiva's score of 0.73 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Inventiva	Positive
Nuvectis Pharma	Positive

19.1% of Inventiva shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 337.98%. Nuvectis Pharma has a consensus price target of $10.00, indicating a potential downside of 3.01%. Given Inventiva's stronger consensus rating and higher possible upside, equities research analysts clearly believe Inventiva is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Inventiva beats Nuvectis Pharma on 10 of the 13 factors compared between the two stocks.

How does Nuvectis Pharma compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

96.8% of Nuvectis Pharma shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alvotech has higher revenue and earnings than Nuvectis Pharma. Alvotech is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	2.12	$27.92M	-$0.25	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Alvotech presently has a consensus target price of $7.60, suggesting a potential upside of 83.57%. Nuvectis Pharma has a consensus target price of $10.00, suggesting a potential downside of 3.01%. Given Alvotech's higher possible upside, equities research analysts clearly believe Alvotech is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alvotech has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

In the previous week, Alvotech had 21 more articles in the media than Nuvectis Pharma. MarketBeat recorded 22 mentions for Alvotech and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.93 beat Alvotech's score of 0.67 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Alvotech	Positive
Nuvectis Pharma	Positive

Nuvectis Pharma has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Summary

Alvotech beats Nuvectis Pharma on 9 of the 14 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$259.95M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-7.87	18.83	24.65	23.63
Price / Sales	N/A	290.77	498.98	104.27
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	14.32	8.00	10.43	6.70
Net Income	-$26.44M	$23.89M	$3.56B	$337.26M
7 Day Performance	10.74%	-3.49%	-1.39%	-1.41%
1 Month Performance	-11.50%	1.03%	0.86%	1.15%
1 Year Performance	14.30%	34.39%	19.42%	22.61%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCT Nuvectis Pharma	0.588 of 5 stars	$10.31 +5.2%	$10.00 -3.0%	+10.7%	$259.95M	N/A	N/A	8
COLL Collegium Pharmaceutical	3.0272 of 5 stars	$30.48 -4.1%	$57.50 +88.6%	+13.0%	$1.03B	$780.57M	14.94	210	Positive News
CRVS Corvus Pharmaceuticals	3.0823 of 5 stars	$11.69 -3.2%	$33.33 +185.1%	+176.5%	$1.02B	N/A	N/A	30
CGEM Cullinan Therapeutics	3.5718 of 5 stars	$15.34 -5.4%	$30.75 +100.5%	+50.5%	$996.23M	N/A	N/A	30	News Coverage Analyst Forecast
IVA Inventiva	2.7151 of 5 stars	$4.09 -14.3%	$16.56 +304.8%	+9.5%	$990.77M	$5.07M	N/A	100	News Coverage Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. COLL, CRVS, CGEM, IVA, and ALVO

How does Nuvectis Pharma compare to Collegium Pharmaceutical?

Summary

How does Nuvectis Pharma compare to Corvus Pharmaceuticals?

Summary

How does Nuvectis Pharma compare to Cullinan Therapeutics?

Summary

How does Nuvectis Pharma compare to Inventiva?

Summary

How does Nuvectis Pharma compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. COLL, CRVS, CGEM, IVA, and ALVO

How does Nuvectis Pharma compare to Collegium Pharmaceutical?

Which has higher valuation & earnings, NVCT or COLL?

Does the media prefer NVCT or COLL?

Which has more risk and volatility, NVCT or COLL?

Is NVCT or COLL more profitable?

Do institutionals and insiders hold more shares of NVCT or COLL?

Do analysts prefer NVCT or COLL?

Summary

How does Nuvectis Pharma compare to Corvus Pharmaceuticals?

Which has more risk & volatility, NVCT or CRVS?

Does the media favor NVCT or CRVS?

Do institutionals & insiders hold more shares of NVCT or CRVS?

Which has preferable valuation & earnings, NVCT or CRVS?

Is NVCT or CRVS more profitable?

Do analysts prefer NVCT or CRVS?

Summary

How does Nuvectis Pharma compare to Cullinan Therapeutics?

Which has more volatility & risk, CGEM or NVCT?

Which has preferable earnings and valuation, CGEM or NVCT?

Does the media refer more to CGEM or NVCT?

Do insiders and institutionals hold more shares of CGEM or NVCT?

Is CGEM or NVCT more profitable?

Do analysts recommend CGEM or NVCT?

Summary

How does Nuvectis Pharma compare to Inventiva?

Which has more risk & volatility, IVA or NVCT?

Which has better valuation and earnings, IVA or NVCT?

Is IVA or NVCT more profitable?

Does the media favor IVA or NVCT?

Do insiders & institutionals hold more shares of IVA or NVCT?

Do analysts recommend IVA or NVCT?

Summary

How does Nuvectis Pharma compare to Alvotech?

Do insiders and institutionals hold more shares of ALVO or NVCT?

Which has stronger valuation and earnings, ALVO or NVCT?

Do analysts rate ALVO or NVCT?

Which has more risk & volatility, ALVO or NVCT?

Does the media prefer ALVO or NVCT?

Is ALVO or NVCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools